Recent advances in our understanding of myeloma progression

Multiple Myeloma Hub
02/06/2020 17 min
Recent advances in our understanding of myeloma progression

Listen "Recent advances in our understanding of myeloma progression"

Descargar episodio Ver en sitio original

Episode Synopsis

During COMy 2020, Multiple Myeloma (MM) Hub steering committee member, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, spoke to the MM Hub about the recent advances in our understanding of myeloma progression.The question remains for patients with smoldering MM: when should therapeutic intervention begin? Here, Irene Ghobrial discusses the need for more robust disease-characterizing and patient-defining criteria. Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast Multiple Myeloma Hub

Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity 23/10/2025
MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM 22/10/2025
How might the clinical development of CELMoDs impact the treatment paradigm for MM? 20/10/2025
CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT 03/10/2025
Evolving diagnostic criteria for high-risk smoldering MM 30/09/2025
What combination regimens including BiTEs are being evaluated for the treatment of RRMM? 17/09/2025
Risk stratification and prognosis in smoldering MM 10/09/2025
What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM? 09/09/2025
How can neurotoxicity associated with CAR T-cell therapy in MM be managed? 26/08/2025
What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD? 18/08/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA